XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues (Tables)
 6 Months Ended
Jun. 30, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue by product and by geographic area
Revenues were as follows (in millions):
Three months ended June 30,
20202019
USROWTotalUSROWTotal
Enbrel® (etanercept)
$1,213  $33  $1,246  $1,315  $48  $1,363  
Prolia® (denosumab)
441  218  659  458  240  698  
Neulasta® (pegfilgrastim)
520  73  593  719  105  824  
Otezla® (apremilast)
464  97  561  —  —  —  
XGEVA® (denosumab)
318  117  435  379  120  499  
Aranesp® (darbepoetin alfa)
156  231  387  192  244  436  
KYPROLIS® (carfilzomib)
167  86  253  166  101  267  
Repatha® (evolocumab)
115  85  200  91  61  152  
Other products1,034  540  1,574  822  513  1,335  
Total product sales(1)
$4,428  $1,480  5,908  $4,142  $1,432  5,574  
Other revenues298  297  
Total revenues$6,206  $5,871  

Six months ended June 30,
20202019
USROWTotalUSROWTotal
ENBREL$2,330  $69  $2,399  $2,421  $93  $2,514  
Prolia®
863  450  1,313  848  442  1,290  
Neulasta®
1,054  148  1,202  1,612  233  1,845  
Otezla®
841  199  1,040  —  —  —  
XGEVA®
673  243  916  735  235  970  
Aranesp®
331  478  809  374  476  850  
KYPROLIS®
354  179  533  320  192  512  
Repatha®
239  190  429  174  119  293  
Other products2,022  1,139  3,161  1,649  937  2,586  
Total product sales(1)
$8,707  $3,095  11,802  $8,133  $2,727  10,860  
Other revenues565  568  
Total revenues$12,367  $11,428  
____________
(1) Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2020 and 2019.